Investigational New Drugs

, Volume 33, Issue 4, pp 977–984 | Cite as

Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer

  • S. M. ReddyEmail author
  • S. Kopetz
  • J. Morris
  • N. Parikh
  • W. Qiao
  • M. J. Overman
  • D. Fogelman
  • I. Shureiqi
  • C. Jacobs
  • Z. Malik
  • C. A. Jimenez
  • R. A. Wolff
  • J. L. Abbruzzese
  • G. Gallick
  • C. Eng


Background Src has a critical role in tumor cell migration and invasion. Increased Src activity has been shown to correlate with disease progression and poor prognosis, suggesting Src could serve as a therapeutic target for kinase inhibition. Saracatinib (AZD0530) is a novel selective oral Src kinase inhibitor. Methods Metastatic colorectal cancer patients who had received one prior treatment and had measurable disease were enrolled in this phase 2 study. Saracatinib was administered at 175 mg by mouth daily for 28 day cycles until dose-limiting toxicity or progression as determined by staging every 2 cycles. The primary endpoint was improvement in 4 month progression-free survival. Design of Thall, Simon, and Estey was used to monitor proportion of patients that were progression free at 4 months. The trial was opened with plan to enroll maximum of 35 patients, with futility assessment every 10 patients. Results A total of 10 patients were enrolled between January and November 2007. Further enrollment was stopped due to futility. Median progression-free survival was 7.9 weeks, with all 10 patients showing disease progression following radiographic imaging. Median overall survival was 13.5 months. All patients were deceased by time of analysis. Observed adverse events were notable for a higher than expected number of patients with grade 3 hypophosphatemia (n = 5). Conclusion Saracatinib is a novel oral Src kinase inhibitor that was well tolerated but failed to meet its primary endpoint of improvement in 4 month progression-free survival as a single agent in previously treated metastatic colorectal cancer patients.


Saracatinib Src inhibitor Colorectal cancer Phase 2 AZD0530 Colon cancer Src kinase 


Compliance with Ethical Standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


This study was presented at AACR 2008 and funded by the National Cancer Institute (NCI Protocol #7565, NSC735464).


  1. 1.
    Siegel R, Desantis C, Jemal A (2014) Colorectal cancer statistics, 2014. CA: Cancer J Clin 64(2):104–17Google Scholar
  2. 2.
    Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol : Off J Am Soc Clin Oncol 22(2):229–37CrossRefGoogle Scholar
  3. 3.
    Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE et al (1999) A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85(4):786–95PubMedCrossRefGoogle Scholar
  4. 4.
    Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM et al (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61(13):5090–101PubMedGoogle Scholar
  5. 5.
    Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D et al (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol : Off J Am Soc Clin Oncol 27(5):672–80CrossRefGoogle Scholar
  6. 6.
    Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360(6):563–72PubMedCrossRefGoogle Scholar
  7. 7.
    Poindessous V, Ouaret D, El Ouadrani K, Battistella A, Megalophonos VF, Kamsu-Kom N et al (2011) EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Clin Cancer Res : Off J Am Assoc Cancer Res 17(20):6522–30CrossRefGoogle Scholar
  8. 8.
    Penuel E, Martin GS (1999) Transformation by v-Src: Ras-MAPK and PI3K-mTOR mediate parallel pathways. Mol Biol Cell 10(6):1693–703PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Xie G, Peng Z, Raufman JP (2012) Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation. Am J Physiol Gastrointest Liver Physiol 302(9):G1006–15PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J et al (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21(13):2000–8PubMedCrossRefGoogle Scholar
  11. 11.
    Chen J, Elfiky A, Han M, Chen C, Saif MW (2014) The role of Src in colon cancer and its therapeutic implications. Clin Colorectal Cancer 13(1):5–13PubMedCrossRefGoogle Scholar
  12. 12.
    Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS et al (2005) HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 24(19):3110–20PubMedCrossRefGoogle Scholar
  13. 13.
    Puls LN, Eadens M, Messersmith W (2011) Current status of SRC inhibitors in solid tumor malignancies. Oncologist 16(5):566–78PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Cartwright CA, Meisler AI, Eckhart W (1990) Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis. Proc Natl Acad Sci U S A 87(2):558–62PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE (2002) Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 94(2):344–51PubMedCrossRefGoogle Scholar
  16. 16.
    Talamonti MS, Roh MS, Curley SA, Gallick GE (1993) Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 91(1):53–60PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Green TP, Fennell M, Whittaker R, Curwen J, Jacobs V, Allen J et al (2009) Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol 3(3):248–61PubMedCrossRefGoogle Scholar
  18. 18.
    Investigator’s Brochure AZD0530 (2005) In: AstraZeneca Pharmaceuticals M, Cheshire, EnglandGoogle Scholar
  19. 19.
    Hennequin L, Allen J, Costello GF et al (2005) The discovery of AZD0530: a novel, oral, highly selective and dual-specific inhibitor of the Src and Abl family kinases. Proc Am Assoc Cancer Res 46:A2537Google Scholar
  20. 20.
    Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI et al (2010) Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res : Off J Am Assoc Cancer Res 16(19):4876–83CrossRefGoogle Scholar
  21. 21.
    Gangadhar TC, Clark JI, Karrison T, Gajewski TF (2013) Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Investig New Drugs 31(3):769–73CrossRefGoogle Scholar
  22. 22.
    Mackay HJ, Au HJ, McWhirter E, Alcindor T, Jarvi A, MacAlpine K et al (2012) A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Investig New Drugs 30(3):1158–63CrossRefGoogle Scholar
  23. 23.
    Fury MG, Baxi S, Shen R, Kelly KW, Lipson BL, Carlson D et al (2011) Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Res 31(1):249–53PubMedCentralPubMedGoogle Scholar
  24. 24.
    Lara PN Jr, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G et al (2009) A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anti-Cancer Drugs 20(3):179–84PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Gucalp A, Sparano JA, Caravelli J, Santamauro J, Patil S, Abbruzzi A et al (2011) Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clin Breast Cancer 11(5):306–11PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Molina JR, Foster NR, Reungwetwattana T, Nelson GD, Grainger AV, Steen PD et al (2014) A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621. Lung Cancer 85(2):245–50PubMedCrossRefGoogle Scholar
  27. 27.
    Messersmith WA NS, Arcaroli J et al. (2010) A phase II trial of saracatinib (AZD0530), an oral Src inhibitor, in previously treated metastatic paancreatic cancer. Journal of Clinical Oncology. Suppl: abstr e14515Google Scholar
  28. 28.
    Laurie SA, Goss GD, Shepherd FA, Reaume MN, Nicholas G, Philip L et al (2014) A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium. Clin Lung Cancer 15(1):52–7PubMedCrossRefGoogle Scholar
  29. 29.
    Renouf DJ, Moore MJ, Hedley D, Gill S, Jonker D, Chen E et al (2012) A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Investig New Drugs 30(2):779–86CrossRefGoogle Scholar
  30. 30.
    McNeish IA, Ledermann JA, Webber L, James L, Kaye SB, Hall M et al (2014) A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Ann Oncol : Off J Eur Soc Med Oncol / ESMO 25(10):1988–95CrossRefGoogle Scholar
  31. 31.
    Griffiths GJ, Koh MY, Brunton VG, Cawthorne C, Reeves NA, Greaves M et al (2004) Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis. J Biol Chem 279(44):46113–21PubMedCrossRefGoogle Scholar
  32. 32.
    Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU et al (2009) Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69(9):3842–9PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA et al (2011) Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene 30(5):561–74PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Koppikar P, Choi SH, Egloff AM, Cai Q, Suzuki S, Freilino M et al (2008) Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res : Off J Am Assoc Cancer Res 14(13):4284–91CrossRefGoogle Scholar
  35. 35.
    Ellis LM, Staley CA, Liu W, Fleming RY, Parikh NU, Bucana CD et al (1998) Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J Biol Chem 273(2):1052–7PubMedCrossRefGoogle Scholar
  36. 36.
    Sharma MR, Wroblewski K, Polite BN, Knost JA, Wallace JA, Modi S et al (2012) Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Investig New Drugs 30(3):1211–5CrossRefGoogle Scholar
  37. 37.
    Strickler JH, McCall S, Nixon AB, Brady JC, Pang H, Rushing C et al (2014) Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Investig New Drugs 32(2):330–9CrossRefGoogle Scholar
  38. 38.
    Lieu C, Wolff RA, Eng C et al. (2010) Phase 1B study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(15 suppl): Abstract 3536Google Scholar
  39. 39.
    Campone M, Bondarenko I, Brincat S, Hotko Y, Munster PN, Chmielowska E et al (2012) Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol : Off J Eur Soc Med Oncol / ESMO 23(3):610–7CrossRefGoogle Scholar
  40. 40.
    Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T et al (2014) Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. Oncologist 19(4):348–9PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • S. M. Reddy
    • 1
    Email author
  • S. Kopetz
    • 2
  • J. Morris
    • 3
  • N. Parikh
    • 4
  • W. Qiao
    • 3
  • M. J. Overman
    • 2
  • D. Fogelman
    • 2
  • I. Shureiqi
    • 2
  • C. Jacobs
    • 2
  • Z. Malik
    • 5
  • C. A. Jimenez
    • 6
  • R. A. Wolff
    • 2
  • J. L. Abbruzzese
    • 7
  • G. Gallick
    • 8
  • C. Eng
    • 2
  1. 1.Hematology-Oncology Fellow, Division of Cancer MedicineThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Gastrointestinal Medical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Department of Biostatistics & Applied MathThe University of Texas MD Anderson Cancer CenterHoustonUSA
  4. 4.Department of Genitourinary Medical Oncology-ResearchThe University of Texas MD Anderson Cancer CenterHoustonUSA
  5. 5.Norton Cancer InstituteLouisvilleUSA
  6. 6.Department of Pulmonary MedicineThe University of Texas MD Anderson Cancer CenterHoustonUSA
  7. 7.Duke Cancer InstituteDurhamUSA
  8. 8.Department of Cancer BiologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations